VORICONAZOLE-INDUCED HEPATOTOXICITY CONCISE UP-TO-DATE REVIEW

Ertem O., GÜMÜŞTEKİN M.

JOURNAL OF BASIC AND CLINICAL HEALTH SCIENCES, cilt.6, sa.1, ss.325-334, 2022 (ESCI) identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 6 Sayı: 1
  • Basım Tarihi: 2022
  • Doi Numarası: 10.30621/jbachs.1051669
  • Dergi Adı: JOURNAL OF BASIC AND CLINICAL HEALTH SCIENCES
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.325-334
  • Anahtar Kelimeler: Voriconazole, Hepatotoxicity, Drug induced liver injury, plasma voriconazole concentration, CYP2C19 genotype, INDUCED LIVER-INJURY, TROUGH CONCENTRATION, EFFICACY, SAFETY, CYP2C19, GENOTYPE, GUIDELINES, EXPERIENCE, EXPOSURE
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Voriconazole is a wide spectrum antifungal used primarily for invasive aspergillosis, an invasive mold infection occurs mostly in immunocompromised patients. Hepatotoxicity is the most common voriconazole-related adverse reaction that leads to treatment discontinuation. Even though reported incidence of hepatic adverse reactions during phase 2 and 3 clinical trials were less than 10%, observational studies in post marketing phase revealed much higher incidence reaching up to 69%. Therefore, the burden caused by hepatotoxicity and interruption of antifungal therapy put immunocompromised patients at serious risk.